Concepedia

Author

J.T. Hartmann

University of Tübingen

Also Known As

J Hartmann, J T Hartmann, J. Hartmann, J. T. Hartmann, J.-T. Hartmann, J.T Hartmann, J.T. Hartmann, JT Hartmann, Jaana Hartmann, J�rgT. Hartmann

108

Publications

5.9K

Citations

36

H-Index

76

Concepts

All Affiliations

University of TübingenMedizinische Hochschule HannoverCharité - Universitätsmedizin BerlinUniversität HamburgCentre Léon Bérard
JH

About

J.T. Hartmann is an author at University of Tübingen specializing in medicine, oncology, and radiation oncology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

20

26

2.7K

2

Health Sciences

5

5

283

3

Engineering

1

1

350

4

Allergy

1

1

10

5

Allergy Medicine

1

1

10

J.T. Hartmann

×

46

Publications

5.1K

Citations

34

H-Index

YearCitations

Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study

Carsten Bokemeyer, Igor Bondarenko, J.T. Hartmann,

Annals of Oncology

2011

778

SSM/I Sea Ice Remote Sensing for Mesoscale Ocean-Atmosphere Interaction Analysis

Lars Kaleschke, Christof Lüpkes, Timo Vihma,

Canadian Journal of Remote Sensing

2001

350

Maintaining success, reducing treatment burden, focusing on survivorship: highlights from the third European consensus conference on diagnosis and treatment of germ-cell cancer

J. Beyer, Peter Albers, Renske Altena,

Annals of Oncology

2012

320

Survival of patients with initially unresectable colorectal liver metastases treated with FOLFOX/cetuximab or FOLFIRI/cetuximab in a multidisciplinary concept (CELIM study)

Gunnar Folprecht, Thomas Gruenberger, Wolf O. Bechstein,

Annals of Oncology

2014

258

KRAS status and efficacy of first-line treatment of patients with metastatic colorectal cancer (mCRC) with FOLFOX with or without cetuximab: The OPUS experience

Carsten Bokemeyer, Igor Bondarenko, J.T. Hartmann,

Journal of Clinical Oncology

2008

241

Secondary leukemia following high cumulative doses of etoposide in patients treated for advanced germ cell tumors.

Christian Kollmannsberger, J. Beyer, Jean‐Pierre Droz,

Journal of Clinical Oncology

1998

204

Hematologic Disorders Associated With Primary Mediastinal Nonseminomatous Germ Cell Tumors

J.T. Hartmann, C R Nichols, J P Droz,

JNCI Journal of the National Cancer Institute

2000

193

First-Line High-Dose Chemotherapy Compared With Standard-Dose PEB/VIP Chemotherapy in Patients With Advanced Germ Cell Tumors: A Multivariate and Matched-Pair Analysis

Carsten Bokemeyer, Christian Kollmannsberger, Christoph Meisner,

Journal of Clinical Oncology

1999

162

Long-Term Results of First-Line Sequential High-Dose Etoposide, Ifosfamide, and Cisplatin Chemotherapy Plus Autologous Stem Cell Support for Patients With Advanced Metastatic Germ Cell Cancer: An Extended Phase I/II Study of the German Testicular Cancer Study Group

Hans‐Joachim Schmoll, Christian Kollmannsberger, Bernd Metzner,

Journal of Clinical Oncology

2003

160

Nilotinib in the treatment of advanced gastrointestinal stromal tumours resistant to both imatinib and sunitinib

Michael Montemurro, Patrick Schöffski, Peter Reichardt,

European Journal of Cancer

2009

148

Page 1